GlassScriptPhysician profile
Melissa Felder
NPI 1386002152
$4,946.47
in general payments reported to CMS, 2019-2025
29 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,987 · 2022: $423 · 2023: $485 · 2024: $996 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $831.98 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $714.64 | 2021-2025 | |
| Janssen Biotech, INC. | $499.41 | 2021-2022 | |
| Novo Nordisk INC | $487.79 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $468.84 | 2021-2025 | Farxiga |
| Emd Serono, INC. | $246.11 | 2024 | Mavenclad |
| Glaxosmithkline, LLC. | $183.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $171.39 | 2021-2023 | |
| Insulet Corporation | $150.37 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.06 | 2021 | |
| Neurocrine Biosciences, INC. | $134.17 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.60 | 2022-2025 | |
| Horizon Therapeutics Plc | $104.92 | 2021 | |
| Lilly USA, LLC | $97.41 | 2021-2025 | Zepbound |
| Ucb, INC. | $90.55 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $87.57 | 2024-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $68.67 | 2021 | |
| Esperion Therapeutics, INC. | $63.35 | 2022-2025 | Nexletol |
| Genzyme Corporation | $44.03 | 2021 | |
| Shield Therapeutics INC | $42.65 | 2023-2024 | Accrufer |
| Mallinckrodt Hospital Products INC. | $41.22 | 2021 | |
| Aurinia Pharma U.S., INC. | $32.69 | 2021 | |
| Pfizer INC. | $31.78 | 2021-2024 | |
| Dexcom, INC. | $18.50 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $17.87 | 2025 | Auvelity |
| Boston Scientific Corporation | $17.64 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $16.05 | 2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $13.48 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $12.20 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Felder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.